VK2735 for Obesity
(VENTURE Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new treatment called VK2735 to determine its effectiveness in promoting weight loss in individuals who are obese or overweight. The research aims to assess the safety and efficacy of VK2735 compared to a placebo (a substance with no active drug). Participants will receive either VK2735 or a placebo once a week. This trial may suit adults with a BMI of 30 or higher, or 27 or higher if they have other related health issues. As a Phase 2 trial, the research focuses on evaluating the treatment's effectiveness in an initial, smaller group of people.
Do I need to stop my current medications for the trial?
The trial requires that you have not used any GLP-1 receptor agonists, GLP-1/GIP dual agonists, or any weight loss medications in the 6 months before screening. Other medications are not specifically mentioned, so it's best to discuss with the trial team.
Is there any evidence suggesting that VK2735 is likely to be safe for humans?
Research has shown that VK2735 was tested in earlier studies and found to be safe and well-tolerated. Participants in these studies did not report any serious side effects, indicating that most people handled the treatment well. VK2735 targets two different parts of the body that help control appetite and weight. Overall, evidence suggests VK2735 is a promising option for those considering joining a clinical trial for weight management.12345
Why are researchers excited about this study treatment for obesity?
Researchers are excited about VK2735 for obesity because it works as a dual agonist of GLP-1 and GIP peptides, which is a different mechanism compared to many current treatments. While standard therapies often focus on just GLP-1 pathways, VK2735 also targets GIP, potentially enhancing weight loss effects. This dual action could offer more significant benefits in appetite regulation and metabolic control, making it a promising option for those who haven't achieved their desired results with existing medications.
What evidence suggests that VK2735 might be an effective treatment for obesity?
Research has shown that VK2735, which participants in this trial may receive, may aid weight loss in people with obesity. In earlier studies, 97% of those taking VK2735 lost at least 5% of their body weight, compared to only 10% of those on a placebo. On average, participants lost up to 12.2% of their starting weight after 13 weeks. Specifically, VK2735 led to about 10.9% more weight loss than the placebo. The treatment affects hormones that regulate appetite and metabolism. These results suggest VK2735 could be a helpful option for weight management in adults with obesity.678910
Are You a Good Fit for This Trial?
This trial is for adults over 18 with obesity (BMI ≥30) or overweight (BMI ≥27) with a weight-related condition, but not heavier than a BMI of 50. It's not for those who've had significant weight changes recently, have diabetes or chronic pancreatitis, used certain drugs for weight loss in the past 6 months, or have specific medical conditions that could affect their participation.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive VK2735 or placebo once weekly for weight management
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Placebo
- VK2735
Find a Clinic Near You
Who Is Running the Clinical Trial?
Viking Therapeutics, Inc.
Lead Sponsor